Brokers Issue Forecasts for Sanara MedTech Q1 Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Sanara MedTech Inc. (NASDAQ:SMTI - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Sanara MedTech in a report issued on Monday, August 18th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.22) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $54.00 target price on the stock. The consensus estimate for Sanara MedTech's current full-year earnings is ($1.10) per share. HC Wainwright also issued estimates for Sanara MedTech's Q2 2026 earnings at ($0.21) EPS, Q3 2026 earnings at ($0.21) EPS and Q4 2026 earnings at ($0.20) EPS.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.10. Sanara MedTech had a negative return on equity of 26.43% and a negative net margin of 10.22%.The firm had revenue of $25.83 million for the quarter, compared to analyst estimates of $25.15 million.

Sanara MedTech Stock Up 11.2%

Shares of NASDAQ SMTI traded up $3.43 during trading on Tuesday, reaching $33.95. 93,685 shares of the stock were exchanged, compared to its average volume of 44,310. The business's 50-day moving average price is $27.92 and its 200 day moving average price is $30.29. Sanara MedTech has a twelve month low of $23.53 and a twelve month high of $39.08. The company has a quick ratio of 2.03, a current ratio of 2.26 and a debt-to-equity ratio of 1.25. The company has a market capitalization of $302.16 million, a price-to-earnings ratio of -29.27 and a beta of 1.26.

Hedge Funds Weigh In On Sanara MedTech

A number of institutional investors have recently added to or reduced their stakes in SMTI. GAMMA Investing LLC increased its position in shares of Sanara MedTech by 8,423.8% during the first quarter. GAMMA Investing LLC now owns 1,790 shares of the company's stock worth $58,000 after acquiring an additional 1,769 shares during the last quarter. Wells Fargo & Company MN grew its stake in Sanara MedTech by 53.9% during the 4th quarter. Wells Fargo & Company MN now owns 1,893 shares of the company's stock valued at $63,000 after purchasing an additional 663 shares in the last quarter. MetLife Investment Management LLC purchased a new stake in Sanara MedTech during the 1st quarter worth approximately $82,000. Lazard Asset Management LLC raised its position in shares of Sanara MedTech by 63,100.0% in the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock valued at $89,000 after purchasing an additional 3,155 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in shares of Sanara MedTech during the 4th quarter valued at approximately $106,000. Institutional investors and hedge funds own 8.10% of the company's stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.